Why is Cancer so Hard? Claudia Fernandes tells us her thoughts… In our second edition of Why is Cancer so Hard? we chat to Claudia Fernandes, Alliances Manager, about her take on why cancer is so difficult to treat and, eventually, cure: Everybody has heard about...
Isogenica renews collaboration with the Royal Academy of Engineering to support students from under-represented groups We are delighted to be working with the Royal Academy of Engineering as part of their Graduate Engineering Engagement Programme (GEEP). The GEEP...
Why is Cancer so Hard? Marion Cubbitt tells us her thoughts… Researchers have been trying to fight cancer for over 100 years, yet there’s still no cure. What makes treating cancer so challenging? We asked our experts at Isogenica for their views: For our Director of...
Isogenica turns 25: Our journey We’ve come a long way over the past quarter century, from our early years as a therapeutic peptide discovery company to specialising in VHH antibodies. Like many long-standing businesses, we’ve been through many changes to get to where...
PEGS 2022: Isogenica showcases plans for implementing machine learning tools Isogenica is attending PEGS Europe: Protein and Antibody Engineering Summit, 14-16th November 2022 Isogenica is delighted to announce we’re attending PEGS Europe 2022. ...
